Neurocrine Biosciences, Inc. today announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease. INGREZZA® SPRINKLE (valbenazine) capsules is now available through the same network of specialty and local affiliated pharmacies that distribute INGREZZA.
Our content is split into different groups. Choose the group that best describes your needs for more information on HD.